Background: Magnetic targeting, which utilizes a magnetic field to specifically deliver
therapeutic agents to the targeted regions, can greatly improve the treatment efficiency. On the other
hand, glucose-modified nanoparticles have also demonstrated good brain-targeting abilities. Fusion
of both might further improve the brain targeting efficiency.
Objective: To prepare, characterize and evaluate glucose-modified ibuprofen-loaded brain targeting
magnetic nanoparticles (MNPs-APS-Glu).
Methods: The magnetic nanoparticles MNPs-APS-Glu were designed and synthesized in order to
effectively deliver ibuprofen to the brain through glucose transporter 1 (GLUT1) and an external
magnetic field. The nanoparticles were characterized by FTIR, SEM and magnetic properties, and
the drug loading capacity, cell cytotoxicity and drug release behavior of the new magnetic nanoparticles
Results: The size of MNPs-APS-Glu was about 104.9 nm, and its drug loading capacity was up to
5%. Furthermore, these brain targeting magnetic nanoparticles maintained the magnetic property
with a saturation magnetization level at ca. 32 emu/g and could release ibuprofen when incubated
with various buffers, mice plasma and brain homogenate.
Conclusions: The results indicated that the magnetic nanoparticles had potential to be a promising
tool to selectively deliver drugs to the brain. This study may be conducive to the field of Central
Nervous System (CNS) drugs delivery.